Merck & Co., Inc. (NYSE:MRK)

Friday’s Top Analyst Upgrades and Downgrades: Walmart, Nvidia, Amgen, Applied Materials, Alibaba, Intel, Merck and More

This has been a rough week for the broad markets, with the S&P 500 and Dow Jones industrial average each down about 3% on last look. What’s shocking is that ...
Read Full Story »

Dividend Investors Have Reasons to Look to Big Biotech Over Big Pharma Ahead

Over the past three decades, the unlimited investing potential of biotechnology was all about growth. Companies could grow from nothing to see untold billions of dollars selling cures and treatments ...
Read Full Story »

Major Pharma Sees Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Arconic, Boston Beer, Disney, Dunkin’, DuPont, GreenSky, IFF, Merck and More

After a big sell-off on Monday and a partial recovery on Tuesday, the markets were indicated to open lower on Wednesday as bond yields continue to slide in the wake ...
Read Full Story »

Why Keytruda Made All the Difference in Merck’s Q2

Merck & Co. Inc. (NYSE: MRK) released its second-quarter financial results before the markets opened on Tuesday. The pharma giant said that it had $1.30 in earnings per share (EPS) ...
Read Full Story »

What to Watch When Merck and Pfizer Report Early on Tuesday

Pfizer Inc. (NYSE: PFE) and Merck & Co. Inc. (NYSE: MRK) are each scheduled to release their second-quarter financial results before the markets open on Tuesday. These are just a ...
Read Full Story »

Apple, Chevron, Exxon, Pfizer, Verizon and More Dow Earnings This Week

Seven of the 30 Dow Jones industrial average components are scheduled to report their latest quarterly reports this week. The Dow is just off its all-time high, while earnings season ...
Read Full Story »

Short Sellers Up the Ante in Big Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

5 Merrill Lynch US 1 Stocks to Buy Also Pay Big and Growing Dividends

With earnings reporting for the second quarter in full swing, and the third quarter of 2019 well underway, many of the top companies we follow on Wall Street are making ...
Read Full Story »

Big Pharma Sees Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Many Top Pharma & Biotechs Rise as Drug Price Disclosure Thrown Out

While the public wants more pharmaceuticals and biotech advancements to treat the endless number of ailments or to extend their lives, there is a simultaneous push to make drugs more ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Barrick Gold, CannTrust, Foot Locker, Inogen, L3Harris, Merck, Petrobras, Starbucks, Symantec, Tesla and More

Stocks were indicated to open marginally higher on Wednesday ahead of the Fourth of July holiday. The S&P 500 and Nasdaq are right at all-time highs after strong stock and ...
Read Full Story »

Short Sellers Seek Direction on Big Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Our Top 10 Stock Moves & News Items for the Week

A lot happened in the world of business during the week of June 14, 2019. The indexes might have been muted with less than 0.5% gains in the Dow and ...
Read Full Story »

High Hopes and Expectations for Merck’s First Investor Day in Years

Merck & Co. Inc. (NYSE: MRK) may still be up in 2019, and it may be better off for now than rival Pfizer, but the reality is that Merck shares ...
Read Full Story »